Organ preservation in early rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether combining chemotherapy and radiation can help people with early-stage rectal cancer keep their rectum and avoid surgery. It is for patients whose tumors have not spread to lymph nodes or other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to give consent.
- You have had a biopsy that confirms rectal adenocarcinoma (a type of cancer in the rectum).
- The tumor is located within 12 cm (about 5 inches) from the anal opening and is staged as T1, T2, or early T3 on MRI.
- MRI shows no signs of cancer spread to lymph nodes or distant organs.
- Your general health is good enough to allow daily activities without help, and your medical team believes both surgery and chemoradiotherapy are possible treatments for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a “total neoadjuvant” treatment plan (medicine given before surgery) that may help some people avoid or reduce surgery for very low rectal cancer. It aims to improve the chance of keeping more normal function while still treating the cancer safely.
This trial tests a strategy to avoid surgery by using watchful waiting after initial treatment for early-stage rectal cancer. It may help patients keep their rectum and avoid a permanent colostomy.
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This study looks at whether some people with locally advanced rectal cancer can safely delay or avoid surgery after chemoradiation by closely monitoring tumors (“watch and wait”). It may help those who strongly want to preserve the anus, but only if they meet strict safety checks.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.